Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemiaMelissa B. Pappalardi, Rab K. Prinjha, Jacques Briand et al.|Nature Cancer|2021Cited by 279